ZBIO News and Press, ProShares UltraPro Short NASDAQ Biotechnology

Riskified Ltd. Class A (RSKD) is expected to report $0.02 for Q4 2025 SunOpta Inc. (STKL) is expected to report $0.05 for Q4 2025 One Liberty Properties Inc. (OLP) is expected to report $0.41 for Q4 2025 Tourmaline Oil Corp (TRMLF) is expected to report $0.35 for Q4 2025 StubHub H...

HCI Group Inc. (HCI) is expected to report $4.87 for Q4 2025 XPEL Inc. (XPEL) is expected to report $0.43 for Q4 2025 Oversea-Chinese Banking Corporation Limited ADR (OVCHY) is expected to report $0.56 for Q4 2025 UMH Properties Inc. (UMH) is expected to report $0.24 for Q4 2025 I...

OGE Energy Corp (OGE) is expected to report $0.3 for Q4 2025 Dana Incorporated (DAN) is expected to report $0.32 for Q4 2025 SiriusPoint Ltd. (SPNT) is expected to report $0.54 for Q4 2025 Nutrien Ltd. (NTR) is expected to report $0.82 for Q4 2025 Broadstone Net Lease Inc. (BNL) i...

Sun Life Financial Inc. (SLF) is expected to report $1.35 for Q4 2025 Copa Holdings S.A. Class A (CPA) is expected to report $4.4 for Q4 2025 Nabors Industries Ltd. (NBR) is expected to report $-2.93 for Q4 2025 Intercorp Financial Services Inc. (IFS) is expected to report $1.1 for Q4...

- Obexelimab met the primary endpoint with a 95% relative reduction in new gadolinium (Gd)-enhancing T1 lesions compared with placebo over weeks 8 and 12 (p=0.0009) - - Separately announced 24-week data support the robust and durable activity of obexelimab and further validate its unique inhi...

2026-02-04 10:16:53 ET More on Zenas BioPharma, Inc. Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease Transcript Zenas: Maintaining 'Strong Buy' As Cross-Trial Comparison Of Obexelimab Should Not Be A Factor ...

WALTHAM, Mass., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of transformative therapies for pat...

2026-01-06 14:58:15 ET Zenas BioPharma, Inc. (ZBIO) Discusses Positive Phase 3 INDIGO Trial Results for Obexelimab in IgG4-Related Disease January 5, 2026 8:00 AM EST... Read the full article on Seeking Alpha For further details see: Zenas BioPharma, Inc. (ZBIO) Discusses Po...

A look at the top 10 most actives in the United States Direxion Daily Semiconductor Bear 3X Shares (SOXS) fell 4.0% to $2.64 on volume of 338,313,823 shares Datavault AI Inc. (DVLT) rose 42.6% to $1.44 on volume of 298,063,233 shares Oriental Culture Holding LTD (OCG) fell 63.3% to $0.0378 ...

2026-01-06 04:58:39 ET The last time I spoke about Zenas BioPharma, Inc. ( ZBIO ), it was regarding a Seeking Alpha article entitled " Zenas: Differentiated B-Cell Targeting Drug With Q3 of 2025 Catalys t". Regarding this article, I went over the fact that the company wa...